2.08p+0.09 (+4.27%)15 Oct 2021, 17:06
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Hemogenyx Pharmaceuticals PLC Fundamentals

Company NameHemogenyx Pharmaceuticals PLCLast Updated2021-10-15
Shares in Issue979.749 mMarket Cap£20.33 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.01EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.1381Debt Equity Ratio0
Asset Equity Ratio1.1938Cash Equity Ratio1.1355
Quick Ratio5.9056Current Ratio5.91
Price To Book Value2.1815ROCE0

Hemogenyx Pharmaceuticals PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Hemogenyx Pharmaceuticals PLC Company Financials

Tangible Assets£268,743.00£233,364.00£173,943.00
Intangible Assets£254,955.00£262,050.00£272,753.00
Total Fixed Assets£747,313.00£495,414.00£446,696.00
Cash & Equivalents£1.81 m£498,679.00£1.76 m
Other Assets000
Total Assets£2.66 m£1.05 m£2.30 m
Creditors within 1 year£1.78 m£181,573.00£167,607.00
Creditors after 1 year£10,028.00£1.22 m£1.17 m
Other Liabilities000
Total Liabilities£1.79 m£1.40 m£1.34 m
Net assets£875,681.00-£349,035.00£959,166.00
Called up share capital£4.34 m£3.61 m£3.60 m
Share Premium£9.99 m£7.70 m£7.34 m
Profit / Loss-£2.10 m-£1.49 m-£1.59 m
Other Equity£890,839.00-£346,518.00£959,166.00
Preference & Minorities-£15,158.00-£2,517.000
Total Capital Employed£875,680.00-£349,035.00£959,166.00
Debt Ratio£0.010£0.55
Assets / Equity1.19381.19381.1938
Cash / Equity1.13551.13551.1355
Cash Flow202020192018
Cash from operating activities-£1.80 m-£1.20 m-£1.35 m
Cashflow before financing£1.41 m-£1.24 m-£171,820.00
Increase in Cash£1.24 m-£1.24 m-£192,041.00
Cost of sales£350,719.00£421,817.00£348,266.00
Gross Profit-£350,719.00-£421,817.00-£348,266.00
Operating Profit-£2.15 m-£1.68 m-£1.68 m
Pre-Tax profit-£2.10 m-£1.49 m-£1.59 m

Hemogenyx Pharmaceuticals PLC Company Background

ActivitiesHemogenyx Pharmaceuticals PLC and its subsidiary is a preclinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy. Its two distinct products include an immunotherapy product for patient conditioning, the CDX bi-specific antibody, and a cell therapy product for BM/HSC transplantation, the HuPHEC.
Latest Interim Date30 Sep 2021
Latest Fiscal Year End Date30 Apr 2021

Hemogenyx Pharmaceuticals PLC Directors

2021-04-30Mr. Peter RedmondNon-Executive Director
2017-10-05Mr. Geoffrey Gilbert DartExecutive Director,Chairman
2018-11-05Mr. Lawrence PembleExecutive Director,Chief Operating Officer
2018-04-03Mr. Adrian Richard Thorpe BeestonNon-Executive Director
2021-05-27Dr. Vladislav SandlerExecutive Director,Chief Executive Officer
2021-05-27Ms. Alexis M. Sandler Non-Executive Director
2019-01-04Dr. Robin CampbellNon-Executive Director
2021-04-30Professor Sir Marc Feldmann AC FRS MB BS PhD FRCP FRCPath FAA F Med SciNon-Executive Director,Chairman

Hemogenyx Pharmaceuticals PLC Contact Details

Company NameHemogenyx Pharmaceuticals PLC
Address5 Fleet Place, London, EC4M 7RD

Hemogenyx Pharmaceuticals PLC Advisors

Financial AdviserPeterhouse Corporate Finance Ltd
Phone+44 2074690930
Fax+44 2072209798
StockbrokerOptiva Securities Ltd
Phone+44 2031371902
SolicitorCharles Russell Speechlys LLP
Phone+44 2072035000
BankMetro Bank Plc
AuditorPKF Littlejohn
Phone+44 2075162200
Fax+44 2075162400
RegistrarComputershare Investor Services PLC
Phone+44 3707020003
Fax+44 3707036101
Financial PR AdviserCamarco
Phone+44 02037574980